ZYKADIA (ceritinib), tyrosine kinase inhibitor

Minor improvement in the treatment of adults with ALK+ advanced non-small cell lung cancer previously treated with crizotinib

• ZYKADIA has conditional Marketing Authorisation as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK+) advanced non-small cell lung cancer previously treated with crizotinib.
• Its efficacy in the third-line treatment of ALK+ lung cancer has been demonstrated in a non-comparative study primarily in terms of overall response rate.
• We still await comparative data versus chemotherapy.